Vensica Medical, a urology therapeutics company, has announced the successful closing of an $11 million funding round to support Phase 2 clinical trials in the United States and Europe for its needle-free treatment of overactive bladder (OAB). The treatment utilizes botulinum toxin A (Xeomin®) delivered via a proprietary, needle-free device.
The investment round was led by Israel Biotech Fund (IBF), with strategic partners Merz, a neurotoxin company, and Laborie, a urology medical device company, also participating. This funding aims to facilitate Vensica's mission to provide a minimally invasive solution for individuals with OAB.
Needle-Free Drug Delivery System
Vensica's technology employs a needle-free drug delivery system to administer Xeomin® directly to the bladder wall. This method is designed to offer a less invasive and potentially more comfortable treatment option for patients compared to traditional injections, which could transform the standard of care for OAB. The company envisions this system as a platform for treating additional bladder indications.
"We are thrilled to have the support of leading investors and partners who share our vision of transforming overactive bladder treatment," said Avner Geva, CEO of Vensica. "This funding will allow us to push forward with Phase 2 trials and move one step closer to bringing this innovative therapy to the patients who need it."
Strategic Partnership with Merz
As part of its strategic partnership with Merz, Vensica has secured exclusive rights to Xeomin® for needle-less therapeutic application in several urologic indications. Vensica will also benefit from Merz's clinical development support. This collaboration marks a significant step forward in the company's goal of delivering next-generation urology treatments.
About Vensica Medical
Vensica Medical is focused on developing novel therapies for urological conditions. Its lead product is a needle-free delivery system for Xeomin® (botulinum toxin A) aimed at treating overactive bladder in a minimally invasive manner. Vensica was established in the incubator program of The Trendlines Group and The Israel Innovation Authority.
